

CLAIMS

What is claims is:

1. A method for treating a patient comprising administering an effective dose of HGF to a patient wherein the patient has a condition characterized as inflammatory
5 bowel disease.

2. The method of claim 1 wherein the patient has a condition selected from the group consisting of Chronic Ulcerative Colitis, Crohn's Disease, necrotizing enterocolitis, severe acute gastroenteritis, chronic gastroenteritis, cholera, chronic infections of the bowel, immunologic disorders affecting the small intestine, immunodeficiency syndromes affecting the small intestine, and HIV.
10

3. The method of claim 1 wherein the administration of HGF is performed systemically.

4. The method of claim 1 wherein the administration of HGF is performed lumenally.

5. The method of claim 1 wherein the effective dosage range of HGF is between about 30 µg/kg body weight/ day to about 300 µg/kg body weight/day.
15

6. The method of claim 1 wherein the effective dose of HGF is about 150 µg/kg body weight/day.

7. A method for treating a patient having intestinal mucosal damage comprising decreasing the mucosal damage of the small intestine by administering an effective dose of HGF to a patient.

5 8. The method of claim 7 wherein the patient has a condition selected from the group consisting of Chronic Ulcerative Colitis, Crohn's Disease, necrotizing enterocolitis, severe acute gastroenteritis, chronic gastroenteritis, cholera, chronic infections of the bowel, immunologic disorders affecting the small intestine, immunodeficiency syndromes affecting the small intestine, and HIV.

10 9. The method of claim 7 wherein the administration of HGF is performed systemically.

10 10. The method of claim 7 wherein the administration of HGF is performed lumenally.

15 11. The method of claim 7 wherein the effective dosage range of HGF is about 30 $\mu\text{g/kg}$ body weight/ day to about 300 $\mu\text{g/kg}$ body weight/day.

12. The method of claim 7 wherein the effective dose of HGF is about 150 $\mu\text{g/kg}$ body weight/day.

13. A method for treating a patient having histologic lesions comprising decreasing the histologic lesions of the small intestine by administering an effective dose of HGF to a patient.

14. The method of claim 13 wherein the patient has a condition selected from the group consisting of Chronic Ulcerative Colitis, Crohn's Disease, necrotizing enterocolitis, severe acute gastroenteritis, chronic gastroenteritis, cholera, chronic infections of the bowel, immunologic disorders affecting the small intestine, immunodeficiency syndromes affecting the small intestine, and HIV.

15. The method of claim 13 wherein the administration of HGF is performed systemically.

16. The method of claim 13 wherein the administration of HGF is performed lumenally.

17. The method of claim 13 wherein the effective dosage range of HGF is about 30 $\mu\text{g/kg}$ body weight/ day to about 300 $\mu\text{g/kg}$ body weight/day.

18. The method of claim 13 wherein the effective dose of HGF is about 150 $\mu\text{g/kg}$ body weight/day.

19. A composition for treating a patient having a condition characterized as inflammatory bowel disease comprising an effective dose of HGF in a suitable carrier.

20. The composition of claim 19 wherein the suitable carrier is selected from
5 the group consisting of intravenous fluid and sustained release enteral preparations.